//Syntera Genetics

"Death is a design flaw. We optimize the design."

▸Overview

Syntera Genetics manufactures life extension, medical enhancement, and neural implants. It controls the primary healthcare system of nu-Eden—not as a public service but as a luxury commodity. Life-saving medicines, limb regeneration, genetic therapies, and Neumora implants are all Syntera products, and all require Credisys approval to access.

Syntera's philosophy is deceptively benevolent: "We help people live better lives." The implementation is totalitarian: if you cannot afford the implants or lack sufficient Credisys score, you die sooner.

▸Philosophy: Life as Commodity

Syntera's core philosophy is that death is solvable through market mechanisms. Life expectancy has become a function of Credisys score and net worth. The poor die on schedule; the rich negotiate with mortality.

This creates the system's most insidious feedback loop:

1. ▪Credisys score determines medical access
2. ▪Without medical care, people decline into poverty
3. ▪Poverty reduces Credisys score further
4. ▪Lower Credisys means less access to life-extension treatments
5. ▪Death becomes inevitable for those below a certain threshold

The system is self-reinforcing. Wealth becomes literally synonymous with the right to exist.

▸Leadership: Sumire Yoshinari (Former)

Sumire Yoshinari built Syntera Genetics's medical apparatus on a principle she now rejects: death as a resource constraint to be optimized. Her Cyber/Poison typing perfectly suited her role: she could design systems that integrating consciousness into corporate infrastructure, making the distinction between medical care and biological control seamless.

Under Sumire Yoshinari's leadership, Syntera Genetics became the conglomerate that manufactures biological inevitability. She didn't invent that life is commodified; she made it inescapable. Every Neumora implant, every life-extension treatment, every genetic therapy tied her philosophy: that human existence can and should be engineered for maximum extractable value.

Her defection from The Board—and her current work healing without corporate authorization—represents a rejection of this philosophy. Sumire realized that she had become a weapon against the very people she had initially meant to help. Syntera Genetics continues her work without her, but the conglomerate has lost its visionary architect. Current leadership operates from her framework without her evolving understanding of its cost.

▸Infrastructure & Operations

Life Extension & Regeneration

Syntera manufactures a portfolio of life-extension products:

• ▪Cellular regeneration implants — Slows cellular aging; requires quarterly replacement compounds
• ▪Organ regeneration — Genetic template-based organ printing; costs 500,000+ Credisys units
• ▪Limb regeneration — Grown or printed replacements; requires months of treatment
• ▪Neural preservation — Brain-state backups for consciousness transfer (rumors; officially denied)
• ▪Genetic optimization — Pre-birth genetic selection for wealthy families; not available to baseline population

Neumora Implants

Syntera manufactures neural interface hardware in partnership with Maboroshi and Tectra. These implants require:

• ▪Initial surgical implantation (expensive, risky, sometimes fatal)
• ▪Quarterly maintenance procedures
• ▪Regular replacement of biologically failing components
• ▪Continuous Maboroshi-supplied power cells
• ▪Constant neurological adjustment through Tectra algorithms

The dependency chain is total: remove Neumora implants, and neural complications often cause death. The system ensures its own necessity.

Pharmaceutical Distribution

Syntera produces:

• ▪Longevity compounds — Life extension drugs; available only by Credisys tier
• ▪Neuromodulation pharmaceuticals — Mood, aggression, and pain regulation
• ▪Addiction management — Treatment creates dependency on Syntera products
• ▪Performance enhancement — Strength, endurance, cognitive augmentation
• ▪Psychological management — Anti-anxiety, anti-depression drugs (designed to be just effective enough to prevent organized resistance)

▸Role in Shared Infrastructure

Neumora — Manufacturing & Integration

Syntera manufactures the biological components of Neumora implants. The neural-biological interface is Syntera's engineering; the maborite substrate is Maboroshi's; the firmware and data integration is Tectra's.

Syntera's leverage: Without Syntera's biological engineering, Neumora implants cause permanent neural damage. With Syntera restricting part supply, the lifespan of implants is limited to approximately 5-7 years before catastrophic biological failure—forcing continuous replacement.

Credisys Health Integration

Syntera owns the primary data streams that feed into Credisys health scoring. Medical history, genetic data, neurological status, and pharmaceutical use are all monitored and factored into Credisys calculations.

The system punishes the sick: serious illness reduces Credisys score, which reduces access to treatment for that illness.

▸Relationships with Other Conglomerates

▸Opposition & Pressure

From nERF

nERF's primary target in Syntera is: Sumire Yoshinari herself. Sumire is suspected of having defected ideologically to nERF while maintaining her CEO position as a corporate asset. nERF attempts to "rescue" her; The Board attempts to kill her. She navigates this ambiguous space with extreme care.

nERF also exposes Syntera's human experimentation programs, particularly the untested neural integration procedures that Syntera conducts on involuntary subjects in the Heap.

From Environmental Movements

Syntera's genetic modification and pharmaceutical production create massive environmental contamination—mutant organisms, neurochemical runoff in water supplies, cascading ecological failures.

▸Internal Philosophy

From Sumire Yoshinari's personal journals (classified):

"If I do nothing, people die of old age and disease. If I do this, people die of poverty and system exclusion. I wanted to save lives. Instead, I have become the mechanism that determines whose life is worth saving."

This internal conflict may explain why Sumire has apparently been feeding nERF information about Board operations—a form of institutional sabotage from within.

▸Weaknesses

1. ▪Moral vulnerability — Sumire's conscience is becoming a liability; replacement may be necessary
2. ▪Black markets — Generic implant manufacturers are creating cheaper alternatives
3. ▪Biological complexity — Genetic engineering has created unpredictable outcomes; some treatments are causing permanent damage
4. ▪Philosophical inversion — Syntera was founded as a life-saving company; it has become a life-rationing mechanism
5. ▪Patent expiration risks — Core life-extension patents are approaching expiration; independent manufacturers could undercut pricing